|
1
|
Lu W, Zhang Y, Liu D, Songyang Z and Wan
M: Telomere-strucutre, function, and regulation. Exp Cell Res.
319:133–141. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Giardini MA, Segatto M, Da Silva MS, Nunes
VS and Cano MIN: Telomere and telomerase biology. Prog Mol Biol
Transl Sci. 125:1–40. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sandin S and Rhodes D: Telomerase
structure. Curr Opin Struct Biol. 25:104–110. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fragkiadaki P, Nikitovic D, Kalliantasi K,
Sarandi E, Thanasoula M, Stivaktakis PD, Nepka C, Spandidos DA,
Tosounidis T and Tsatsakis A: Telomere length and telomerase
activity in osteoporosis and osteoarthritis. Exp Ther Med.
19:1626–1632. 2020.PubMed/NCBI
|
|
5
|
Fragkiadaki P, Tsoukalas D, Fragkiadoulaki
I, Psycharakis C, Nikitovic D, Spandidos DA and Tsatsakis AM:
Telomerase activity in pregnancy complications (Review). Mol Med
Rep. 14:16–21. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Razgonova MP, Zakharenko AM, Golokhvast
KS, Thanasoula M, Sarandi E, Nikolouzakis K, Fragkiadaki P,
Tsoukalas D, Spandidos DA and Tsatsakis A: Telomerase and telomeres
in aging theory and chronographic aging theory (Review). Mol Med
Rep. 22:1679–1694. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vakonaki E, Tsiminikaki K, Plaitis S,
Fragkiadaki P, Tsoukalas D, Katsikantami I, Vaki G, Tzatzarakis MN,
Spandidos DA and Tsatsakis AM: Common mental disorders and
association with telomere length. Biomed Rep. 8:111–116.
2018.PubMed/NCBI
|
|
8
|
Vasilopoulos E, Fragkiadaki P, Kalliora C,
Fragou D, Docea AO, Vakonaki E, Tsoukalas D, Calina D, Buga AM,
Georgiadis G, et al: The association of female and male infertility
with telomere length (Review). Int J Mol Med. 44:375–389.
2019.PubMed/NCBI
|
|
9
|
Murofushi Y, Nagano S, Kamizono J,
Takahashi T, Fujiwara H, Komiya S, Matsuishi T and Kosai K: Cell
cycle-specific changes in hTERT promoter activity in normal and
cancerous cells in adenoviral gene therapy: A promising implication
of telomerase-dependent targeted cancer gene therapy. Int J Oncol.
29:681–688. 2006.PubMed/NCBI
|
|
10
|
Yeh JK, Lin MH and Wang CY: Telomeres as
therapeutic targets in heart disease. JACC Basic to Transl Sci.
4:855–865. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Page MJ, McKenzie JE, Bossuyt PM, Boutron
I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan
SE, et al: The PRISMA 2020 statement: An updated guideline for
reporting systematic reviews. BMJ. 372:n712021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Seimiya H, Oh-hara T, Suzuki T, Naasani I,
Shimazaki T, Tsuchiya K and Tsuruo T: Telomere shortening and
growth inhibition of human cancer cells by novel synthetic
telomerase inhibitors MST-312, MST-295, and MST-1991. Mol Cancer
Ther. 1:657–665. 2002.PubMed/NCBI
|
|
13
|
Wang SJ and Yang PM: A bioinformatics
analysis identifies the telomerase inhibitor MST-312 for treating
High-STMN1-expressing hepatocellular carcinoma. J Pers Med.
11:3322021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Altamura G, Degli Uberti B, Galiero G, De
Luca G, Power K, Licenziato L, Maiolino P and Borzacchiello G: The
small molecule BIBR1532 exerts potential anti-cancer activities in
preclinical models of feline oral squamous cell carcinoma through
inhibition of telomerase activity and down-regulation of TERT.
Front Vet Sci. 7:6207762021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pandya VA, Crerar H, Mitchell JS and
Patani R: A non-toxic concentration of telomerase inhibitor
BIBR1532 fails to reduce TERT expression in a feeder-free induced
pluripotent stem cell model of human motor neurogenesis. Int J Mol
Sci. 22:32562021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pascolo E, Wenz C, Lingner J, Hauel N,
Priepke H, Kauffmann I, Garin-Chesa P, Rettig WJ, Damm K and
Schnapp A: Mechanism of human telomerase inhibition by BIBR1532, a
synthetic, non-nucleosidic drug candidate. J Biol Chem.
277:15566–15572. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang Y, Cheng FX, Yuan XL, Tang WJ, Shi
JB, Liao CZ and Liu XH: Dihydropyrazole derivatives as telomerase
inhibitors: Structure-based design, synthesis, SAR and anticancer
evaluation in vitro and in vivo. Eur J Med Chem. 112:231–251. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Thelen P, Wuttke W, Jarry H, Grzmil M and
Ringert RH: Inhibition of telomerase activity and secretion of
prostate specific antigen by silibinin in prostate cancer cells. J
Urol. 171:1934–1938. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nasiri M, Zarghami N, Koshki KN,
Mollazadeh M, Moghaddam MP, Yamchi MR, Esfahlan RJ, Barkhordari A
and Alibakhshi A: Curcumin and silibinin inhibit telomerase
expression in T47D human breast cancer cells. Asian Pac J Cancer
Prev. 14:3449–3453. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen X, Zha GF, Wang JQ and Liu XH:
Ethenesulfonyl fluoride derivatives as telomerase inhibitors:
structure-based design, SAR, and anticancer evaluation in vitro. J
Enzyme Inhib Med Chem. 33:1266–1270. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Man RJ, Chen LW and Zhu HL: Telomerase
inhibitors: A patent review (2010–2015). Expert Opin Ther Pat.
26:679–688. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hu MH, Lin XT, Liu B and Tan JH: Dimeric
aryl-substituted imidazoles may inhibit ALT cancer by targeting the
multimeric G-quadruplex in telomere. Eur J Med Chem.
186:1118912020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Thompson CAH, Gu A, Yang SY, Mathew V,
Fleisig HB and Wong JMY: Transient telomerase inhibition with
imetelstat impacts DNA damage signals and cell-cycle kinetics. Mol
Cancer Res. 16:1215–1225. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Burchett KM, Etekpo A, Batra SK, Yan Y and
Ouellette MM: Inhibitors of telomerase and poly(ADP-ribose)
polymerases synergize to limit the lifespan of pancreatic cancer
cells. Oncotarget. 8:83754–83767. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tremblay D and Mascarenhas J: Next
generation therapeutics for the treatment of myelofibrosis. Cells.
10:10342021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ghareghomi S, Ahmadian S, Zarghami N and
Hemmati S: hTERT-molecular targeted therapy of ovarian cancer cells
via folate-functionalized PLGA nanoparticles co-loaded with
MNPs/siRNA/wortmannin. Life Sci. 277:1196212021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Roe S, Gunaratnam M, Spiteri C, Sharma P,
Alharthy RD, Neidle S and Moses JE: Synthesis and biological
evaluation of hybrid acridine-HSP90 ligand conjugates as telomerase
inhibitors. Org Biomol Chem. 13:8500–8504. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Meng T, Qin QP, Wang ZR, Peng LT, Zou HH,
Gan ZY, Tan MX, Wang K and Liang FP: Synthesis and biological
evaluation of substituted 3-(2′-benzimidazolyl)coumarin
platinum(II) complexes as new telomerase inhibitors. J Inorg
Biochem. 189:143–150. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Le Saux CJ, Davy P, Brampton C, Ahuja SS,
Fauce S, Shivshankar P, Nguyen H, Ramaseshan M, Tressler R, Pirot
Z, et al: A novel telomerase activator suppresses lung damage in a
murine model of idiopathic pulmonary fibrosis. PLoS One.
8:e584232013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kim YJ, Yoo JE, Jeon Y, Chong JU, Choi GH,
Song DG, Jung SH, Oh BK and Park YN: Suppression of PROX1-mediated
TERT expression in hepatitis B viral hepatocellular carcinoma. Int
J Cancer. 143:3155–3168. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li J, Zhang N, Zhang R, Sun L, Yu W, Guo
W, Gao Y, Li M, Liu W, Liang P, et al: CDC5L promotes hTERT
expression and colorectal tumor growth. Cell Physiol Biochem.
41:2475–2488. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen R, Zhu J, Dong Y, He C and Hu X:
Suppressor of Ty homolog-5, a novel tumor-specific human telomerase
reverse transcriptase promoter-binding protein and activator in
colon cancer cells. Oncotarget. 6:32841–32855. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Qin Y, Chen W, Xiao Y, Yu W, Cai X, Dai M,
Xu T, Huang W, Guo W, Deng W and Wu T: RFPL3 and CBP
synergistically upregulate hTERT activity and promote lung cancer
growth. Oncotarget. 6:27130–27145. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Stefanou N, Papanikolaou V, Furukawa Y,
Nakamura Y and Tsezou A: Leptin as a critical regulator of
hepatocellular carcinoma development through modulation of human
telomerase reverse transcriptase. BMC Cancer. 10:4422010.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yu P, Shen X, Yang W, Zhang Y, Liu C and
Huang T: ZEB1 stimulates breast cancer growth by up-regulating
hTERT expression. Biochem Biophys Res Commun. 495:2505–2511. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sanokawa-Akakura R, Akakura S and
Tabibzadeh S: Replicative senescence in human fibroblasts is
delayed by hydrogen sulfide in a NAMPT/SIRT1 dependent manner. PLoS
One. 11:e01647102016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Akiyama M, Kawano T, Mikami-Terao Y,
Agawa-Ohta M, Yamada O, Ida H and Yamada H: Erythropoietin
activates telomerase through transcriptional and
posttranscriptional regulation in human erythroleukemic JAS-REN-A
cells. Leuk Res. 35:416–418. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wei ZZ, Qin QP, Chen JN and Chen ZF:
Oxoisoaporphine as potent telomerase inhibitor. Molecules.
21:15342016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Herz C, Hertrampf A, Zimmermann S, Stetter
N, Wagner M, Kleinhans C, Erlacher M, Schüler J, Platz S, Rohn S,
et al: The isothiocyanate erucin abrogates telomerase in
hepatocellular carcinoma cells in vitro and in an orthotopic
xenograft tumour model of HCC. J Cell Mol Med. 18:2393–4203. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Adler S, Rashid G and Klein A:
Indole-3-carbinol inhibits telomerase activity and gene expression
in prostate cancer cell lines. Anticancer Res. 31:3733–3737.
2011.PubMed/NCBI
|
|
41
|
Taka T, Changtam C, Thaichana P,
Kaewtunjai N, Suksamrarn A, Lee TR and Tuntiwechapikul W:
Curcuminoid derivatives enhance telomerase activity in an in vitro
TRAP assay. Bioorg Med Chem Lett. 24:5242–5246. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yu Y, Zhou L, Yang Y and Liu Y:
Cycloastragenol: An exciting novel candidate for age-associated
diseases. Exp Ther Med. 16:2175–2182. 2018.PubMed/NCBI
|
|
43
|
Akbarizare M, Ofoghi H and Hadizadeh M:
Dual effect of sapogenins extracted from spirulina platensis on
telomerase activity in two different cell lines. Mol Biol Res
Commun. 10:1–4. 2021.PubMed/NCBI
|
|
44
|
Chu WK and Hickson ID: RecQ helicases:
Multifunctional genome caretakers. Nat Rev Cancer. 9:644–654. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Uchiumi F, Watanabe T, Hasegawa S, Hoshi
T, Higami Y and Tanuma S: The effect of resveratrol on the Werner
syndrome RecQ helicase gene and telomerase activity. Curr Aging
Sci. 4:1–7. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Tsoukalas D, Buga AM, Docea AO, Sarandi E,
Mitrut R, Renieri E, Spandidos DA, Rogoveanu I, Cercelaru L,
Niculescu M, et al: Reversal of brain aging by targeting
telomerase: A nutraceutical approach. Int J Mol Med. 48:1992021.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Tsoukalas D, Zlatian O, Mitroi M, Renieri
E, Tsatsakis A, Izotov BN, Burada F, Sosoi S, Burada E, Buga AM, et
al: A novel nutraceutical formulation can improve motor activity
and decrease the stress level in a murine model of middle-age
animals. J Clin Med. 10:6242021. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Tsoukalas D, Fragkiadaki P, Docea AO,
Alegakis AK, Sarandi E, Thanasoula M, Spandidos DA, Tsatsakis A,
Razgonova MP and Calina D: Discovery of potent telomerase
activators: Unfolding new therapeutic and anti-aging perspectives.
Mol Med Rep. 20:3701–3708. 2019.PubMed/NCBI
|
|
49
|
Looi LM, Ng MH and Cheah PL: Telomerase
activation in neoplastic cell immortalization and tumour
progression. Malays J Pathol. 29:33–35. 2007.PubMed/NCBI
|
|
50
|
Shay JW and Keith N: Targeting telomerase
for cancer therapeutics. Br J Cancer. 98:677–683. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Andrews LG and Tollefsbol TO: Methods of
telomerase inhibition. Methods Mol Biol. 405:1–7. 2008. View Article : Google Scholar
|
|
52
|
Trybek T, Kowalik A, Góźdź S and Kowalska
A: Telomeres and telomerase in oncogenesis. Oncol Lett.
20:1015–1027. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Bu X, Jia F, Wang W, Guo X, Wu M and Wei
L: Coupled down-regulation of mTOR and telomerase activity during
fluorouracil-induced apoptosis of hepatocarcinoma cells. BMC
Cancer. 7:2082007. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Barthel FP, Wei W, Tang M,
Martinez-Ledesma E, Hu X, Amin SB, Akdemir KC, Seth S, Song X, Wang
Q, et al: Systematic analysis of telomere length and somatic
alterations in 31 cancer types. Nat Genet. 49:349–357. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Nikolouzakis TK, Vakonaki E, Stivaktakis
PD, Alegakis A, Berdiaki A, Razos N, Souglakos J, Tsatsakis A and
Tsiaoussis J: Novel prognostic biomarkers in metastatic and locally
advanced colorectal cancer: Micronuclei frequency and telomerase
activity in peripheral blood lymphocytes. Front Oncol.
11:6836052021. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Hashizume R, Ozawa T, Gryaznov SM, Bollen
AW, Lamborn KR, Frey WH II and Deen DF: New therapeutic approach
for brain tumors: Intranasal delivery of telomerase inhibitor
GRN163. Neuro Oncol. 10:112–120. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Renieri E, Vakonaki E, Karzi V,
Fragkiadaki P and Tsatsakis AM: Telomere length: associations with
nutrinets and xenobiotics. In: Toxicological Risk Assessment and
Multi-System Health Impacts from Exposure. Academic Press.
pp295–306. 2021.
|
|
58
|
Shay JW: Telomerase therapeutics:
Telomeres recognized as a DNA damage signal: Commentary re: K.
Kraemer et al, antisense-mediated hTERT inhibition
specifically reduces the growth of human bladder cancer cells.
Clin. Cancer Res. 9:3794–3800. 2003.Clin Cancer Res 9: 3521–3525,
2003. PubMed/NCBI
|
|
59
|
Martinez P and Blasco MA: Telomere-driven
diseases and telomere-targeting therapies. J Cell Biol.
216:875–887. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Sugarman ET, Zhang G and Shay JW: In
perspective: An update on telomere targeting in cancer. Mol
Carcinog. 58:1581–1588. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Smith-Sonneborn J: Telomerase biology
associations offer keys to cancer and aging therapeutics. Curr
Aging Sci. 13:11–21. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Bernardes de Jesus B, Vera E, Schneeberger
K, Tejera AM, Ayuso E, Bosch F and Blasco MA: Telomerase gene
therapy in adult and old mice delays aging and increases longevity
without increasing cancer. EMBO Mol Med. 4:691–704. 2012.
View Article : Google Scholar : PubMed/NCBI
|
